Embracing Differences: Our journey to diversity, equity, and inclusion
Embracing Differences: Our journey to diversity, equity, and inclusion
Search
Generalized pustular psoriasis: The importance of support and collaboration to promote advances in the GPP community
Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD
Championing Novel Science
Championing Novel Science
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Why today’s depression trials demand smart new approaches
Why today’s depression trials demand smart new approaches
Bigger Role in Ensuring Food Security | Boehringer Ingelheim US
As the population of the earth grows, animal health becomes fundamental in ensuring well-being and the global protein supply. Click here to find out more.
Scleroderma
Scleroderma
Contact Us
Contact Us
Looking Ahead at Recruitment in the Biopharma Industry
Looking Ahead at Recruitment in the Biopharma Industry
Galym Zhunisbekov
Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, talks about our philosophy and impact on patients’ lives.
Reducing Stress in Horses – With Music
Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".
Lung Diseases
Our Therapeutic Areas
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Pushing for Progress
Pushing for Progress
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Coliform Mastitis: the facts to know | Boehringer Ingelheim US
Click here to learn more about different management practices that can help you to improve your dairy herd's bottom line and productivity.
FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism
FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism
Championing for people with all abilities
Every diverse background brings unique perspectives to our company.
FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)
FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
Ridgefield, Connecticut, home to our U.S. headquarters, is ranked #1 safest place to live
Read about what makes Ridgefield, Connecticut a great place to live, work, and make a difference in the lives of people and animals.
Boehringer Ingelheim Celebrates 50th Anniversary in the U.S. by Committing Up to $450,000 to Nonprofit Partners
Boehringer Ingelheim Celebrates 50th Anniversary in the U.S. by Committing Up to $450,000 to Nonprofit Partners
Exploring beyond boundaries for innovation in animal health
Exploring beyond boundaries by partnering with human pharma and animal health may hold the key to accelerating innovation in animal health.
Our Partners: ViraTherapeutics
Our Partners: ViraTherapeutics
Low-WAC interchangeable biosimilar is now available
Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.